FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2340640928> ?p ?o ?g. }

• W2340640928 endingPage "198" @default.
• W2340640928 startingPage "186" @default.
• W2340640928 abstract "Population-based information on cancer incidence, prevalence and outcome are required to inform clinical practice and research; but contemporary data are lacking for many myeloid malignancy subtypes. Set within a socio-demographically representative UK population of ∼4 million, myeloid malignancy data (N = 5231 diagnoses) are from an established patient cohort. Information on incidence, survival (relative & overall), transformation/progression, and prevalence is presented for >20 subtypes. The median diagnostic age was 72.4 years (InterQuartile Range 61.6–80.2), but there was considerable subtype heterogeneity, particularly among the acute myeloid leukaemias (AML) where medians ranged from 20.3 (IQR 13.9–43.8) for AML 11q23 through to 73.7 (IQR 57.3–79.1) for AML with no recurrent genetic changes. Five-year Relative Survival (RS) estimates varied hugely; from <5% for aggressive entities like therapy-related AML (2.6%, 95% Confidence Interval 0.4–9.0) to >85% for indolent/treatable conditions like chronic myeloid leukaemia (89.8%, 95% CI 84.0–93.6). With a couple of notable exceptions, males experienced higher rates and worse survival than females: the age-standardized incidence rates of several conditions was 2–4 higher in males than females, and the 5-year RS for all subtypes combined was 48.8% (95% CI 46.5–51.2) and 60.4% (95% CI 57.7–62.9) for males and females respectively. During follow-up (potential minimum 2 years and maximum 11 years) myelodysplastic syndrome (MDS) progression to AML ranged from 25% for refractory anaemia with excess blasts through to 5% for refractory anaemia with ring sideroblasts: the median interval between MDS and AML diagnosis was 9.0 months (IQR 4.8–17.4 months). The marked incidence and outcome variations seen by subtype, sex and age, confirm the requirement for “real-world” longitudinal data to inform aetiological hypotheses, healthcare planning, and future monitoring of therapeutic change. Several challenges for routine cancer registration were identified, including the need to link more effectively to diagnostic and clinical data sources, and to review policies on the recording of progressions and transformations." @default.
• W2340640928 created "2016-06-24" @default.
• W2340640928 creator A5000441901 @default.
• W2340640928 creator A5003414034 @default.
• W2340640928 creator A5026080770 @default.
• W2340640928 creator A5027760913 @default.
• W2340640928 creator A5078478289 @default.
• W2340640928 creator A5078781310 @default.
• W2340640928 creator A5083456305 @default.
• W2340640928 creator A5090807802 @default.
• W2340640928 date "2016-06-01" @default.
• W2340640928 modified "2023-10-06" @default.
• W2340640928 title "Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK’s population-based Haematological Malignancy Research Network 2004–15" @default.
• W2340640928 cites W1491098094 @default.
• W2340640928 cites W1549301208 @default.
• W2340640928 cites W1880134390 @default.
• W2340640928 cites W1966327132 @default.
• W2340640928 cites W1967008538 @default.
• W2340640928 cites W1970101456 @default.
• W2340640928 cites W1974085479 @default.
• W2340640928 cites W1979715239 @default.
• W2340640928 cites W1986769067 @default.
• W2340640928 cites W1992106582 @default.
• W2340640928 cites W2009650262 @default.
• W2340640928 cites W2009854509 @default.
• W2340640928 cites W2011814974 @default.
• W2340640928 cites W2016969330 @default.
• W2340640928 cites W2017085228 @default.
• W2340640928 cites W2017984932 @default.
• W2340640928 cites W2018195863 @default.
• W2340640928 cites W2018930152 @default.
• W2340640928 cites W2021395262 @default.
• W2340640928 cites W2025837443 @default.
• W2340640928 cites W2035098923 @default.
• W2340640928 cites W2053666216 @default.
• W2340640928 cites W2054163626 @default.
• W2340640928 cites W2057051793 @default.
• W2340640928 cites W2063619313 @default.
• W2340640928 cites W2067057833 @default.
• W2340640928 cites W2068366821 @default.
• W2340640928 cites W2074015360 @default.
• W2340640928 cites W2078294866 @default.
• W2340640928 cites W2091092110 @default.
• W2340640928 cites W2095442126 @default.
• W2340640928 cites W2102205601 @default.
• W2340640928 cites W2102215044 @default.
• W2340640928 cites W2107398329 @default.
• W2340640928 cites W2109997465 @default.
• W2340640928 cites W2112657305 @default.
• W2340640928 cites W2116858301 @default.
• W2340640928 cites W2119868861 @default.
• W2340640928 cites W2120890793 @default.
• W2340640928 cites W2121367684 @default.
• W2340640928 cites W2131098741 @default.
• W2340640928 cites W2154220906 @default.
• W2340640928 cites W2168083201 @default.
• W2340640928 cites W2414732399 @default.
• W2340640928 cites W4300955920 @default.
• W2340640928 doi "https://doi.org/10.1016/j.canep.2016.03.011" @default.
• W2340640928 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4911595" @default.
• W2340640928 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27090942" @default.
• W2340640928 hasPublicationYear "2016" @default.
• W2340640928 type Work @default.
• W2340640928 sameAs 2340640928 @default.
• W2340640928 citedByCount "84" @default.
• W2340640928 countsByYear W23406409282016 @default.
• W2340640928 countsByYear W23406409282017 @default.
• W2340640928 countsByYear W23406409282018 @default.
• W2340640928 countsByYear W23406409282019 @default.
• W2340640928 countsByYear W23406409282020 @default.
• W2340640928 countsByYear W23406409282021 @default.
• W2340640928 countsByYear W23406409282022 @default.
• W2340640928 countsByYear W23406409282023 @default.
• W2340640928 crossrefType "journal-article" @default.
• W2340640928 hasAuthorship W2340640928A5000441901 @default.
• W2340640928 hasAuthorship W2340640928A5003414034 @default.
• W2340640928 hasAuthorship W2340640928A5026080770 @default.
• W2340640928 hasAuthorship W2340640928A5027760913 @default.
• W2340640928 hasAuthorship W2340640928A5078478289 @default.
• W2340640928 hasAuthorship W2340640928A5078781310 @default.
• W2340640928 hasAuthorship W2340640928A5083456305 @default.
• W2340640928 hasAuthorship W2340640928A5090807802 @default.
• W2340640928 hasBestOaLocation W23406409281 @default.
• W2340640928 hasConcept C119060515 @default.
• W2340640928 hasConcept C120665830 @default.
• W2340640928 hasConcept C121332964 @default.
• W2340640928 hasConcept C121608353 @default.
• W2340640928 hasConcept C126322002 @default.
• W2340640928 hasConcept C143998085 @default.
• W2340640928 hasConcept C2778527826 @default.
• W2340640928 hasConcept C2778729363 @default.
• W2340640928 hasConcept C2779399171 @default.
• W2340640928 hasConcept C2780007613 @default.
• W2340640928 hasConcept C2780558122 @default.
• W2340640928 hasConcept C2780817109 @default.
• W2340640928 hasConcept C2908647359 @default.
• W2340640928 hasConcept C44249647 @default.
• W2340640928 hasConcept C61511704 @default.

• next